Commissural alignment and the ACURATE neo2 transcatheter aortic valve: Impact on valve performance
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31089 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Alejandro Travieso und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Heart Center, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis, Aortic Valve Stenosis, Prosthesis Design. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Transcatheter aortic valve replacement (TAVR) is increasingly being used to treat severe aortic stenosis in younger patients. Accordingly, lifetime management regarding future reintervention and coronary access is a concern.
Aims
To assess the impact of commissural alignment on ACURATE neo 2 transcatheter aortic valve (TAV) performance.
Methods
COMALIGN‐neo2 was an observational, retrospective study enrolling consecutive TAVR patients treated with the ACURATE neo 2 (October 2021 to October 2022). The degree of commissural (mis)‐alignment (CMA) with the native aortic valve commissures was determined and transvalvular gradient, effective orifice area, patient‐prosthesis mismatch (PPM), and aortic regurgitation (AR) were assessed.
Results
Among 825 patients, the mean age was 80.7 years and 42% were female. Commissural alignment was achieved in 60% of cases; mild (26%), moderate (9%), and severe misalignment (5%) were found less often. Severe PPM occurred more frequently in patients with severe CMA (14.7%) compared to aligned valves ( p = 0.034). By multivariate analysis, severe CMA (odds ratio [OR]: 3.12, 95% confidence interval [CI] [1.09–8.90]; p = 0.033) and lack of postdilatation (OR: 3.85, [1.33–11.1]; p = 0.012) were associated with severe PPM. Higher rates of ≥mild AR (51.4%) were found in TAVs implanted with severe CMA compared to aligned (34.3%), mildly (38.1%) or moderately (36.0%) misaligned TAVs ( p = 0.030). Multivariate analysis identified severe CMA (OR: 2.05, [1.05–4.02]; p = 0.037) to be an independent predictor of ≥mild AR.
Conclusions
COMALIGN‐neo2 is the largest study to date assessing the impact of commissural alignment on acute TAV performance. Severe CMA with the ACURATE neo2 platform was associated with worse valve hemodynamics and increased risk for mild AR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Heart Center, Rigshospitalet, Copenhagen, Denmark.
- Heart Center Lucerne, Lucerner Kantonsspital, Lucerne, Switzerland.
- Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany.
- Department of Cardiac Surgery, Kerckhoff Heart Center, Bad Nauheim, Germany.
- DZHK (German Center for Cardiovascular Research), Site Rhein-Main, Bad Nauheim, Germany.
- Department of Cardiology, Justus Liebig University of Giessen and Marburg, Giessen, Germany.
ORCID-Profile: Alejandro Travieso, Nicholas Montarello
Zitieren
APA
Travieso, A., Toggweiler, S., Montarello, N., Renker, M., Tirado-Conte, G., Loretz, L., Charitos, E. I., Kim, W. K., & De Backer, O. (2024). Commissural alignment and the ACURATE neo2 transcatheter aortic valve: Impact on valve performance. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31089
Vancouver
Travieso A, Toggweiler S, Montarello N, Renker M, Tirado-Conte G, Loretz L, et al. Commissural alignment and the ACURATE neo2 transcatheter aortic valve: Impact on valve performance. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31089
BibTeX
@article{Travieso2024,
author = {Travieso, Alejandro and Toggweiler, Stefan and Montarello, Nicholas and Renker, Matthias and Tirado-Conte, Gabriela and Loretz, Lucca and Charitos, Efstratios I and Kim, Won-Keun and De Backer, Ole},
title = {Commissural alignment and the ACURATE neo2 transcatheter aortic valve: Impact on valve performance},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31089}
}
EUVIMED